Forgent Power Solutions Inc. Class A Common Stock vs Johnson & Johnson — how do they compare? Forgent Power Solutions Inc. Class A Common Stock trades at $32.19 (market cap $9.93B), while Johnson & Johnson trades at $257.81 (market cap $599.12B). The key difference: Johnson & Johnson is far larger — about 60.3× Forgent Power Solutions Inc. Class A Common Stock's market cap, and Johnson & Johnson pays a 2.16% dividend while Forgent Power Solutions Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Forgent Power Solutions Inc. Class A Common Stock for 0 Days and Johnson & Johnson for 129 Days on average.
| FPS | JNJ | |
|---|---|---|
Market Cap | $9.93B | $599.12B |
Volume | 7,516,726 | 16,640,951 |
Sector | Industrials | Health |
52-Week High | $64.59 | $278.43 |
52-Week Low | $27.97 | $186.00 |
Typical Hold Time | 0 Days | 129 Days |
Enterprise Value | $10.54B | $627.40B |
Dividend Yield | — | 2.16% |
Signals from Pluang's Aura AI — not financial advice
Forgent Power Solutions (FPS) trades at $36.17, down 2.48% on the day, following a strong earnings-driven rally. The stock shows neutral technical signals with support at $35 and resistance at $37. Recent Q2 2026 earnings beat expectations with EPS of $0.25 versus $0.24 expected, continuing a pattern of quarterly outperformance. The company reported record $3 billion backlog and strong data center demand driving growth.
FPS presents significant upside potential with analyst consensus target of $55.20 (52.9% upside) and 85.7% buy ratings. However, high valuation multiples (P/E 120.57, P/S 6.21) and negative 2025 net income of -$6.17M create valuation concerns. Key risks include execution on $3B backlog and potential overvaluation amid AI infrastructure hype.
JNJ trades at $253.91, down 3.72% on the day, amid a mixed technical and fundamental backdrop. The stock shows strong profitability with a 21.48% net income margin and 25.74% ROE, supported by three consecutive quarterly EPS beats. Analyst consensus is bullish with a $282.73 price target, though recent news highlights competitive pressures and patent cliff concerns. Cash flow trends indicate robust operations but elevated investing outflows.
The outlook remains positive given JNJ's diversified healthcare portfolio and innovation pipeline, but investors face risks from debt levels rising to 24.06% of assets and biosimilar competition. Near-term resistance lies at $265, with support at $257. Institutional sentiment favors growth in pharmaceuticals and medical technology, though macroeconomic and regulatory headwinds persist.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Forgent Power Solutions designs and manufactures electrical distribution equipment, including transformers, switchgear, transfer switches, and prefabricated power systems, for data centers, the power grid, and industrial facilities, manufacturing across multiple product categories in-house through a network of manufacturing campuses in US.
Read more on FPS →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →